Literature DB >> 6640506

Central nervous system metastasis from breast carcinoma. Autopsy study.

Y Tsukada, A Fouad, J W Pickren, W W Lane.   

Abstract

Central nervous system (CNS) metastasis was noted in 309 patients of 1044 autopsy cases of breast carcinoma. The brain was involved in 193 cases, and cranial dura in 167 cases. In 82 cases, the cranial dura was the sole site of CNS involvement. Metastasis to the leptomeninges was found in 59 cases, and to the spinal cord and dura in 32 cases. Metastases to the infratentorial portion of the brain was almost as frequent as to the cerebrum. Forty-two percent of the brain metastasis were single lesions, which is similar to the frequency of solitary metastasis to the brain from malignant tumors as a whole. CNS metastasis occurred more frequently in younger patients than older patients, and the clinical course of these patients was shorter than for those patients without CNS metastasis. CNS metastasis developed in the late stage of the disease, and often was not recognized clinically. Only 31% of the cases were clinically diagnosed or suspected before death. A median survival of these patients after clinical diagnosis of CNS metastasis was 33 days. However, a significant improvement was noted in the clinical diagnosis and median survival in the latter half of the study period. Eleven patients lived for more than 1 year after diagnosis of CNS metastasis. Only 14% of the 309 patients died from CNS failure.

Entities:  

Mesh:

Year:  1983        PMID: 6640506     DOI: 10.1002/1097-0142(19831215)52:12<2349::aid-cncr2820521231>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  161 in total

Review 1.  Meningeal metastases: clinical aspects and diagnosis.

Authors:  F Formaglio; A Caraceni
Journal:  Ital J Neurol Sci       Date:  1998-06

2.  Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.

Authors:  Hee-Jun Kim; Seock-Ah Im; Bhumsuk Keam; Yu-Jung Kim; Sae-Won Han; Tae Min Kim; Do-Youn Oh; Jee Hyun Kim; Se-Hoon Lee; Eui Kyu Chie; Wonshik Han; Dong-Wan Kim; Tae-You Kim; Dong-Young Noh; Dae Seog Heo; In Ae Park; Yung-Jue Bang; Sung Whan Ha
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

3.  Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies.

Authors:  Javier Puente Vázquez; Sara López-Tarruella Cobo; José A García-Sáenz; Antonio Casado Herráez; Fernando Moreno Antón; Teresa Sampedro Gimeno; Coralia Bueno Muiño; Enrique Grande Pulido; Miguel Martín Jiménez; Eduardo Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

Review 4.  Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

Authors:  Ankit I Mehta; Adam M Brufsky; John H Sampson
Journal:  Cancer Treat Rev       Date:  2012-06-22       Impact factor: 12.111

Review 5.  Patterns of metastasis and natural courses of breast carcinoma.

Authors:  Y T Lee
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 6.  CNS complications of breast cancer: current and emerging treatment options.

Authors:  Evert C A Kaal; Charles J Vecht
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  Systemic therapy of brain metastases.

Authors:  Harry C Brastianos; Daniel P Cahill; Priscilla K Brastianos
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

8.  Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.

Authors:  Mohamed Ismail Nounou; Chris E Adkins; Evelina Rubinchik; Tori B Terrell-Hall; Mohamed Afroz; Tim Vitalis; Reinhard Gabathuler; Mei Mei Tian; Paul R Lockman
Journal:  Pharm Res       Date:  2016-08-15       Impact factor: 4.200

9.  Response of brain metastases from breast cancer to megestrol acetate: a case report.

Authors:  D J Stewart; S Dahrouge
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

10.  Effect of HER2 status on distant recurrence in early stage breast cancer.

Authors:  Kenneth R Hess; Francisco J Esteva
Journal:  Breast Cancer Res Treat       Date:  2012-12-06       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.